Santé log

AIM ImmunoTech Signs Agreement for Planning of a Proposed Phase 3 Clinical Trial of Ampligen in the Treatment of Late-Stage Pancreatic Cancer

See: AIM ImmunoTech Announces Planned Milestones in the Ongoing Phase 2 Trial of Ampligen and AstraZeneca’s Durvalumab in the Treatment of Metastatic Pancreatic Cancer ...
Santé log

Coherus Oncology to Report Full Year and Fourth Quarter 2025 Financial Results on March 9, 2026

Coherus Oncology, Inc. (Nasdaq: CHRS), today announced that its full year and fourth quarter 2025 financial results will be released after market close on Monday, March 9, 2026. Starting at 4:30 p.m.
Santé log

Biomimetic Innovations Ltd Announces Upcoming Clinical Study of OsStic™ Injectable Synthetic Bone Void Filler in Tibial Plateau Fracture Fixation

SHANNON, Ireland, March 02, 2026 (GLOBE NEWSWIRE) -- Biomimetic Innovations Ltd, an affiliate of PBC Biomed, an Irish medical device company specialising in biomimetic materials, today announced ...
Santé log

Election of employee representatives to the Board of Directors of Novo Nordisk A/S

The newly elected employee representatives will join the Board of Directors following the annual general meeting of Novo Nordisk A/S on 26 March 2026. At the same time, the current board members ...
Santé log

Tilray Brands Acquires BrewDog, a Leading Global Craft Brand, Creating a ~$500 Million Global Craft Beer and Beverage Platform

Accretive Acquisition of Select Assets Includes Global Brand, UK Brewing Operations and 11 Strategic Brewpubs . Expected to Generate ~$200 Million in Annual Net Revenue and ~$6 - ...
Santé log

Allogene Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update

Listen-Only Webcast The listen-only webcast will be made available on the Company's website at www.allogene.com under the Investors tab in the News and Events section. A replay will be available on ...
Santé log

HCW Biologics Regains Compliance with All Continued Listing Rules for Nasdaq Per Nasdaq Determination Letter

HCW Biologics Inc. (the “Company” or “HCW Biologics”) (Nasdaq: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by ...
Santé log

FibroBiologics, Inc. Announces Issuance of U.S. Patent Covering Fibroblast Cell Therapy for the Treatment of Osteoporosis

The patent covers methods of treating bone diseases or disorders, including osteoporosis, through the administration of fibroblast cells. The claims encompass systemic or local administration of ...
Santé log

Award-Winning Speaker Mike Veny Launches “Coffee with Mike” Mental Health Podcast for Workplace Leaders

As a workplace mental health speaker and Certified Corporate Wellness Specialist®, Veny developed the mental health podcast to reach more leaders seeking meaningful approaches to improving well-being ...
Santé log

Interra Health, created through the merger of DoseSpot and Arrive Health, ushers in a new era of transparency for patients and providers

Interra Health, formed today by the merger of DoseSpot and Arrive Health, delivers the first patient-centric prescribing experience, providing trusted eligibility, price transparency and pharmacy ...
Santé log

Living with a Rare Disease: A Pastor’s Journey Finding the Right Care and Treatment for NF1-PN

A Media Snippet accompanying this announcement is available by clicking on this link.
Santé log

Ascendis Pharma to Participate in the TD Cowen 46th Annual Health Care Conference

COPENHAGEN, Denmark, March 02, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that company executives will participate in a virtual fireside chat at the TD Cowen 46th ...